期刊文献+

银屑病生物治疗的常见问题与对策 被引量:5

Common Problems and Countermeasures in the Treat-ment of Psoriasis with Biologic Agents
下载PDF
导出
摘要 生物制剂在银屑病中的应用越来越广泛,已经成为中重症和难治性病例的重要治疗手段,在特殊类型银屑病的治疗中也发挥着积极的作用。临床实践中,不同患者的病情和个体情况千差万别,在是否应用生物制剂、选择何种生物制剂以及具体的使用方法和安全性等方面还存在各种各样的问题需要解决,临床医生应从患者病情与健康背景、治疗需求和既往治疗反应、生物制剂作用机制和安全性特点等多方面进行综合评估,做出恰当的选择。 With expanding applications for psoriasis indications,biologic agents have become an essential remedy for moderate-to-severe cases,and played a positive part in special type psoriasis.However,in clinical practice,disease condition and individual situation varies from patient to patient,thus healtheare providers still face a lot of challenges when it comes to if it's the time to use biologics,what's the best choice,how to use a biologic agent and if it's safe enough,etc.Clinicians should make appropriate choice based on comprehensive assessment encompassing the patient's disease condition and overall health,demand for treatment,previous therapeutic response,and mechanism of action and safelty characteristics of biologics.
作者 王刚 WANG Gang(Department of Dermatology,Xijing Hospital,Fourth Military Medical University,Shaanxi,710032,China)
出处 《皮肤科学通报》 2020年第5期521-524,M0007,共5页 Dermatology Bulletin
关键词 银屑病 生物制剂 治疗 Psoriasis Biologic agents Treatment
  • 相关文献

参考文献8

二级参考文献38

  • 1刘新,梁瑞霞.异烟肼与利福平联用预防结素强阳性人群发病的观察[J].中原医刊,2004,31(18):55-55. 被引量:3
  • 2Brassard P, Lowe AM, Bernatsky S, et al. Rheumatoid arthritis, its treatments, and the risk of tuberculosi in Quebec, Canada.Arthritis Rheum, 2009, 6t: 300-304.
  • 3Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol, 2007, 34:706-711.
  • 4Carmona L, Hemandez-Gareia C, Vadillo C, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatoh 2003, 30: 1436-1439.
  • 5Gomez-Reino JJ, Cannona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multi- center active-surveillance report. Arthritis Rheum, 2003, 48: 2122-2127.
  • 6Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis, 2006, 43: 717-722.
  • 7Chen DY, Shen GH, Lan JL, et al. Biphasic emergence of ac-tire tuberculosis in rheumatoid arthritis patients receiving TNF-ot inhibitors: the utility of IFN-T assay. Ann Rheum Dis, 2012, 71 : 231-237.
  • 8Singh JA, Furst DE, Bharat A, et 81. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hobo- ken), 2012, 64: 625-639.
  • 9Chen DY, Shen GH, Hsieh TY, et al. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum, 2008, 59: 800-806.
  • 10Miyasaka N, Takeuchi T, Eguchi K. Gyidelines for the proper use of etanercept in Japan. Mod Rheumatol, 2006, 16: 63-67.

共引文献164

同被引文献46

引证文献5

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部